Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Guidant Galileo

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement is filed with FDA for a next-generation version of the intravascular radiation system for in-stent restenosis that incorporates an automated "stepping function" to automatically reposition the radiation source and facilitate treatment of long lesions. Called the GalileoIII, the device uses a third generation centering catheter, Guidant explains. The current version of the system, approved Nov. 2, permits treatment of long lesions via manual tandem repositioning (1"The Gray Sheet" Nov. 12, 2001, p. 3). Pending approval, customers with existing systems will be upgraded at no additional cost, the firm says...

You may also be interested in...

Guidant Galileo Expanded Intravascular Radiation Indications Slated For 2002

Guidant plans to pursue FDA approval of expanded indications for its Galileo beta-emitting intravascular radiation system to treat small vessels and long lesions by the second half of 2002

Butterfly Network’s CEO Sees Blank Check Deal As Path To ‘Democratize’ Portable Imaging Platform

Butterfly Network chose SPAC route with Longview Acquisition Corp. to scale its business and expand into the home market in 2021.

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts